Logistics Live: Conversations & Insights on the Global Supply Chain

Setting Up a Robust CGT Supply Chain (Part 2)

Today we continue our conversation with Mike Sweeney, Global Head of Strategy for Cell & Gene Therapies and Direct to Patient products at QuickSTAT Global Life Science Logistics, on how to set up a robust CGT supply chain. 
In Part 1, Mike described the explosion of cell and gene therapies registered for clinical trials – plus the hope and supply chain logistics challenges that growth provides. 
In Part 2, Mike discusses the benefits of advanced planning, the role of technology, as well as cold chain and chain of custody. We began, however, with his analysis of the ongoing regulatory change globally. I asked Mike: How does QuickSTAT stay on top of it, and what type of guidance do they give?

Setting Up a Robust CGT Supply Chain (Part 1)

Cell & Gene Therapies hold incredible potential for improving – if not saving – human lives. These CGT’s have been called “living drugs” and can heal diseased organs and – we hope – fight diseases that currently have no cure. 
Because of these incredible possibilities, related research and development is growing exponentially around the globe, with increasing numbers of complex clinical trials – complex because they require precisely-timed pickup and delivery of specimens and therapies. A single hiccup anywhere in terms of pickup, drop-off, temperature – anything – can cause significant challenges.
So what, exactly, does it take to set up a robust Cell & Gene Therapy supply chain? What should manufacturers, labs, pharmaceutical & biotech companies, and logistics providers consider? 
Mike Sweeney can explain. Mike is Global Head of Strategy for CGT and Direct to Patient products (CGT and DTP) at QuickSTAT Global Life Science Logistics. He joins me now to discuss why – for CGT Supply Chains – planning in advance is the best medicine.

Establishing Direct-to and from-Patient Clinical Trials (Part 2)

In Part 2, Mike Sweeney, QuickSTAT’s Global Head of Strategy for CGT and Direct to Patient products, offers specific supply chain design ideas and tactics to establish processes and overcome potential logistics roadblocks. He breaks down extraordinary case studies, and gives his views on what’s next – particularly around regulation.

Establishing Direct-to and from-Patient Clinical Trials (Part 1)

Critically ill patients increasingly can participate in life saving and life changing cell & gene therapy clinical trials without having to leave their homes with the Direct- to -Patient and Direct- from -Patient model. So how do you set up these supply chains? How do you mitigate risk? And how do you ensure they’re resilient? Mike Sweeney, QuickSTAT’s Global Head of Strategy for CGT and Direct to Patient products, explains.